Advanced searches left 3/3

Carcinoma Esophagus - Crossref

Summarized by Plex Scholar
Last Updated: 19 November 2022

* If you want to update the article please login/register

Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma

Background: Barrett's esophagus can progress to esophageal adenocarcinoma, a tumor with an increasing incidence and poor survival. We discuss the prevalence and risk factors for BE and EAC, as well as how they may influence healthcare. Methods: We searched PubMed and Cochrane databases for English-language publications using the keywords Barrettu2019s esophagus and esophageal adenocarcinoma. Results: During the last five decades, the prevalence of BE and EAC has increased in many regions, particularly in North America, Northwestern Europe, and Australia. GERD and obesity are now extremely common in Asia, indicating that the prevalence of EAC is likely to increase globally. Conclusions: The increasing prevalence of GERD, obesity, and Helicobacter pylori infection infect can contribute to rising EAC incidence rates around the world. EAC mortality can be reduced by targeted screening programs that use a combination of risk factors for BE and EAC.

Source link: https://doi.org/10.1177/26345161221138045


Radiation Induced Liver Injury: Collateral Damage Radiologically Simulating Interval Metastasis in Carcinoma Esophagus; a Diagnostic Dilemma Resolved Through Liver Biopsy

Both for baseline measurement and analysis of treatment response, F-18-fluorodeoxyglucose positron emission tomography is increasingly being used in patients with cancer. In patients with incidental irradiation of the liver during radiotherapy, particularly for lower gastrointestinal tract cancers, increasing focal F-18-fluorodeoxyglucose positron emission tomography avidity may have been the result of collateral radiation-induced liver damage rather than metastases. A liver biopsy confirmed malignancy and helped to clinch the correct diagnosis of radiation-induced liver injury.

Source link: https://doi.org/10.1177/10668969221095181


Biological markers of Barrett’s esophagus progression to adenocarcinoma

Barrett's esophagus is a condition in which a stratifi ed squamous epithelium of the distal esophagus is replaced by a metaplastic intestinal-type columnar epithelium. Epithelial dysplasia is the only clinically useful indicator of the risk of development carcinoma in BE, and it is now used in practice. The most important genetic and molecular measurements that can support the presence of diagnostic or predictive biological markers in BE are considered within the context of this review.

Source link: https://doi.org/10.31146/1682-8658-ecg-177-5-91-98


High Serum Squamous Cell Carcinoma Antigen Level Associated with Remission of Mild/Moderate Dysplasia of the Esophagus: A Nested Case–Control Study

The aim of this research was to investigate the relationship between the serum squamous cell carcinoma antigen and remission of esophageal squamous mild or moderate dysplasia. During the years of 2013-2013u20132018, patients with mild/moderate dysplasia of the esophageal squamous epithelium were enrolled in this study, which was followed by a follow-up endoscopy. The result of dysplasia was determined by a predictive model based on the variables of SCCA, age, sex, education level, and baseline dysplasia grade. To determine the diagnostic effectiveness of the regression status of dysplasia under the predictive model, a receiver operating characteristic curve was used. A decline or stable diagnosis of dysplasia was reported by 100 patients, and 46 patients had a progressed status. Increased serum SCCA levels were correlated with regressed severity of mild and moderate dysplasia of the esophageal mucosa. Further research was warranted, and SCCA serum concentration was a potential biomarker for dysplasia prognosis.

Source link: https://doi.org/10.1155/2022/2961337


Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy

Methods: We determine molecular subtypes of patients and develop a predictive model for subtype classification based on the DNA methylation and gene expression profiles of ESCC patients. In an independent validation cohort of Chinese ESCC patients receiving immunotherapy, the clinical value of molecular subtypes for the prediction of immunotherapy effectiveness is evaluated. Results: We found two molecular subtypes of ESCC that are linked to specific immune-related pathways, tumor microenvironment, and clinical outcomes. According to reports, S2 subtype patients had a poorer prognosis. In the S1 subtype of immunotherapy, the response rate is much higher than in the S2 subtype patients.

Source link: https://doi.org/10.3390/cancers14204970


Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus

ESO-26 and low TROP2 positive OACM5. 1C showed heightened sensitivity to SG in comparison to negative FLO-1. The ESO-26 tumor has a significantly higher response to SG than the TROP2-negative FLO-1 tumor in vivo. As before therapy, FLO-1 is consistently negative, while ESO-26 vital tumor cells display similar TROP2 expression on all carcinoma cells. Discussion: Our results show that sacituzumab govitecan, as well as the extent of treatment response by sacituzumab govitecan, is a novel therapy option in esophageal adenocarcinoma and the TROP2 expression in irinotecan-nau00efve EAC in irinotecan-naefve EAC.

Source link: https://doi.org/10.3390/cancers14194789


656. EPIMIOLOGICAL ASPECTS OF PROGRESSION FROM BARRETT'S ESOPHAGUS IN DYSPLASIA AND ESOPHAGEAL ADENOCARCINOMA: LONG FOLLOW UP IN A HIGH VOLUME CENTER

Abstract Barrett's Esophagus affects approximately 3 million people in Brazil, and an increase in the incidence of the disease has been observed in recent years. Patients with BE with long follow-up at Hospital das Clu00ednicas da Faculdade de Medicina da Universidade de Su00e3o Paulo finding epidemiological risk factors connected with a higher risk of BE progression to dysplasia and adenocarcinoma. This study revealed that males, smoke, and white patients, as opposed to patients with long Barrett's epythelium, were at a greater risk of experiencing dysplasia and adenocarcinoma.

Source link: https://doi.org/10.1093/dote/doac051.656


585. INDIAN SINGLE CENTRE EXPERIENCE USING CROSS PROTOL IN CARCINOMA ESOPHAGUS AND GASTROESOPHAGEAL JUNCTION (GEJ)

Abstract The treatment of esophageal cancer has changed for the last decade. By the Dutch CROSS procedure, Neoadjuvant chemoradiation followed by surgery has been found to be particularly effective in locally advanced esophageal and GEJ tumors. The aim of neoadjuvant therapy is to raise R0 resection, down staging, and pathological complete response, which then increases disease-free and overall survival. This is a prospective observational single arm review of 51 patients who were treated with neoadjuvant chemoradiation with radiation therapy to 41. 4 Gy/23 Fr/4. 5 weeks and weekly paclitaxel and carboplatin, followed by surgery at our hospital between 2013 and 2021. Squamous cell carcinoma in 90% of patients was present in 90% of patients. All patients received the recommended dose of radiation; 11/51 patients experienced a hospitalization due to haematological toxicity; one patient died; 11/51 patients received a treatment delay; 11/51 patients had a delay due to haematological toxicity; 11/51 patients had a treatment delay due to haematological toxicity; one patient died. Our results with neoadjuvant chemo radiation therapy are in accordance with published results. Surgery post-induction therapy was not associated with increased morbidity, according to the author.

Source link: https://doi.org/10.1093/dote/doac051.585


544. NON-EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOEPITHELIOMA-LIKE CARCINOMA OF THE ESOPHAGUS WITH SURGICAL TREATMENT: A REPORT OF TWO CASES

In the lower esophagus, a submucosal tumor was discovered during a gastroenterologic endoscopy. Case 2 was a 71-year-old man who was found to have a tumor in the esophagus by barium examination and was referred to our hospital. Submucosal tumor was found 23-26 cm from the cut tooth, according to upper gastrointestinal endoscopy. The specimen from case 1 was positive for AE1/AE3, P40, and negative for chromogranin A, but not positive for u03b1SMA and desmin. In the specimen from both patients, EBV was not detected by EBER in situ hybridization. EBV that directly infects epithelial cells or infects lymphocytes is very common in salivary glands, thymus, stomach, skin, and cervix, and cervix.

Source link: https://doi.org/10.1093/dote/doac051.544

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions